Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin

Circulation

Volumn 101, Issue 13, 2000, Pages 1598-1605

  Miller, Leslie W ^a,b   Dai, Erbin ^b,c   Nash, Piers ^b,d   Liu, Liying ^b,c   Icton, Carolyn ^c   Klironomos, Dennis ^c   Fan, Lilly ^c   Nation, Patric N ^b   Zhong, Robert ^b,d   McFadden, Grant ^b,c,d   Lucas, Alexandra ^b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Inflammation; Rejection; Serpin; Transplantation; Viruses

Indexed keywords

ALLOANTIGEN; ANTIINFLAMMATORY AGENT; CD2 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INVASION; CONTROLLED STUDY; DNA VIRUS; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; MONONUCLEAR CELL; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RAT; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

EID: 0034603822     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.13.1598     Document Type: Article

References (46)

1. Brann WM, Keck BM, Bennett LE, Hosenpud JD. Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant. 1998;17:374-382.
2. Miller LW. Complications of cardiac transplantation. Prog Cardiovasc Dis. 1991;33:229-282.
3. Halloran PF, Miller LW. In vivo immunosuppressive mechanisms. J Heart Lung Transplant. 1996;15:959-971.
4. Vanbuskirk AM, Pidwell DJ, Adams PW, Orosz CG. Transplantation immunology. JAMA. 1997; 278:1993-1999.
5. Kobashigawa J, Ratkovec R, Miller L, Hummel M, Renlund D, Ipe D, Mentzer R, Johnson J, Alderman E, Keogh A, Bourge R, Mamelok R, Costanzo M, Mancini D, Eisen H, Smart F, Dureau G, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients: Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515.
6. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, Yacoub M, Banner N, Gandjbakhch I, Dorent R, Hetzer R, Hummel M. European Multicenter Tacrolimus (FK506) Heart Pilot Study: 1-year results in the European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant. 1998;17:775-781.
7. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP, Brozena SC, Dec GW, Ventura HO, Kirlin JK, Bourge RC, Miller LW, and the Cardiac Transplant Research Database. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 1998;17:744-753.
8. Yeung A, Davis S, Hauptman P, Kobashigawa J, Miller L, Valantine H, Ventura H, Wiedermann J, Wilensky R. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant. 1995;14:S215-S220.
9. Hayry P, Myllarniemi M, Aavik E. Chronic allograft rejection. Transplant Proc. 1996;28:2337-2338.
10. Hauptman P, Nakagawa T, Tanaka H, Libby P. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant. 1995;14:S173-S180.
11. Gao SZ, Schroeder JS, Hunt SA, Stinson EB. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant. 1993;12:1029-1035.
12. Lamich R, Ballester M, Marti V, Brossi V, Aymat R, Carrio I, Berna L, Camprecios M, Puig M, Estorch M, Flotats A, Bordes R, Garcia J, Auge J, Padro J, Caralps JM, Narula J. Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. J Am Coll Cardiol. 1998;32:413-419.
13. Terasaki PI, Gjertson DW, Cecka JM, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333:333-336.
14. Takada M, Nadeau K, Hancock W, Mackenzie H, Shaw G, Waaga AM, Chandraker A, Sayegh M, Tilney N. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998; 65:1533-1542.
15. Day JD, Rayburn BK, Gaudin PB, Baldwin WM, Lowenstein CJ, Kasper EK, Baughman KL, Baumgartner WA, Hutchins GM, Hruban RH. The central pathogenic role of ischemia induced endothelial cell injury. J Heart Lung Transplant. 1995;14:S142-S149.
16. Land W, Messmer K. The impact of ischemia/reperfusion injury on specific and non-specific early and late chronic events after organ transplantation. Transplant Rev. 1996;10:108-127.
17. Kobashigawa JA, Katnelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
18. Hoang K, Chen I, Reaven G, Zhang L, Ross H, Billingham M, Valantine H. Diabetes and dyslipidemia: a new model for transplant coronary disease. Circulation. 1998;97:2160-2168.
19. Gupta A, Moustapha A, Jacobsen DW, Goormastic M, Tuzcu EM, Hobbs R, Young J, James K, McCarthy P, Van Lente F, Green R, Robinson K. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation. 1998;65:544-550.
20. Fay L. Cytomegalovirus and coronary artery disease in heart transplant patients: accelerated low density lipoprotein and lipoprotein (A) modification as a proposed factor. J Heart Lung Transplant. 1993;12:155. Letter.
21. Russell ME. Macrophages and transplant arteriosclerosis: known and novel molecules. J Heart Lung Transplant. 1995;14:S111-S114.
22. Demetris AJ, Murase N, Ye Q, Galvao FHF, Richert C, Saad R, Pham S, Duquesnoy RJ, Zeevi A, Fung JJ, Starzi TE. Analysis of chronic rejection and obliterative arteriopathy: possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol. 1997;150: 563-578.
23. Ross R. Atherosclerosis: a defense mechanism gone awry (Rous-Whipple award lecture). Am J Pathol. 1993;143:987-1002.
24. Reidy M, Irvin C, Lindner V. Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 1996;78:405-414.
25. More RS, Underwood MJ, Brack MJ, DeBobo DP, Gershlick AH. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury. Cardiovasc Res. 1995;29:22-26.
26. Ragno P, Monturi N, Rossi G. Urokinase type plasminogen activator receptor associates to a cell surface molecule in monocytic cells. Biochem Biophys Acta. 1996;224:252-257.
27. Lucas A, Liu L, Macen J, Nash P, Dai E, Stewart M, Graham K, Etches W, Boshkov L, Nation PN, Humen D, Lundstrom-Hobman M, McFadden G. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation. 1996;94:2890-2900.
28. Lupu F, Heim DA, Bachman F, Hunri M, Kakkar VV, Kruithof KO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vase Biol. 1995;15:1444-1455.
29. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive, and chemotactic highways? Trends Immunol Today. 1997;18:415-417.
30. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J. 1995;9:934-938.
31. Allaire E, Hasenstab D, Kenagy RD, Starcher B, Clowes MM, Clowes AW. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation. 1998;98:249-255.
32. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Ann Rev Immunol. 1996;14:101-130.
33. Ploegh HL. Viral strategies of immune evasion. Science. 1998;280: 248-253.
34. Turner PC, Musy PY, Moyer RW. Poxvirus serpins. In: McFadden G. ed. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin, Texas: RG Landes Co; 1995:67-88.
35. Barry M, McFadden G. Virus encoded cytokines and cytokine receptors. Parasitology. 1997;115:S89-S100.
36. Nash P, Whitty A, Handwerker J, Macen J, McFadden G. Inhibitory specificity of the anti-myxoma virus serpin, SERP-1. J Biol Chem. 1998; 273:20982-20991.
37. Nash P, Lucas A, McFadden G. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. In: Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, eds. Chemistry and Biology of Serpins. New York, NY: Oxford University Press; 1997:195-205.
38. Maksymowych W, Nation N, Nash P, Macen J, Lucas A, McFadden G, Russell AS. Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. J Rheumatol. 1996;23:878-882.
39. Lee HC, Ahn KJ, Lim SK, Kim KR, Ahn YS, Lee KE, Huh KB. Allotransplantation of rat islets into the cisterna magna of streptozotocininduced diabetic rats. Transplantation. 1992;53:513-516.
40. Pundt LL, Kondoh T, Conrad JA, Low WC. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res Bull. 1996;39:23-32.
41. Mennander A, Raisanen A, Poavonene T, Hayry P. Chronic rejection in the rat aortic allograft, V: mechanism of the angiopeptin (BIM23014C) effect on the generation of allograft atherosclerosis. Transplantation. 1993;55:124-128.
42. Garvin MR, Walley VM, Labinaz M, Mizgala HF, Pels K, O'Brien ER. Arterial expression of the plasminogen activator system early after cardiac transplantation. Cardiovasc Res. 1997;35:241-249.
43. Goes N, Urmson J, Vincent D, Halloran P. Acute renal injury in the interferon-γ gene knockout mouse: effect on cytokine gene expression. Transplantation. 1995;60:1560-1564.
44. Tang WH, Freiss H, diMola FF, Schilling M, Maurer C, Graber HU, Dervenis C, Zimmermann A, Buchler MW. Activation of the serine proteinase system in chronic renal rejection. Transplantation. 1998;65: 1628-1634.
45. Katznelson S, Wang XM, Chia D, Ozawa M, Zong HP, Hirata M, Terasaki PI, Kobashigawa JA. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 1998;17:335-340.
46. Shi C, Russell ME, Blanchi C, Newell JB, Haber E. Murine model of accelerated transplant arteriosclerosis. Circ Res. 1994;75:199-207.